MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ejhf.70071

Медицинская библиотека · European journal of heart failure · 2025

Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.

Porcari Aldostefano, Milani Paolo, Longhi Simone, Cappelli Francesco, Vagnarelli Fabio, Aimo Alberto, Cipriani Alberto, Gardini Elisa, Marazia Stefania, Monda Emanuele, Tini Giacomo, Musumeci Beatrice, Serenelli Matteo, Cantone Anna, Lofiego Carla, Marini Marco, Vergaro Giuseppe, Foti Grazia, Musca Francesco, Tomasoni Daniela, Bonacchi Giacomo, Colio Federica, Sinigiani Giulio, De Michieli Laura, Sturdà Francesca, Pozzan Marco, Gentile Piero, Carigi Samuela, Bartolotti Michela, Sena Giuseppe, Ruotolo Irene, Sanna Giuseppe Damiano, Zanoletti Margherita, Canepa Marco, Di Marco Massimo, D'Elia Emilia, Di Bella Gianluca, Driussi Mauro, Imazio Massimo, Perfetto Federico, Biagini Elena, Limongelli Giuseppe, Metra Marco, Emdin Michele, Merlini Giampaolo, Perlini Stefano, Merlo Marco, Palladini Giovanni, Sinagra Gianfranco

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

AIMS: Tafamidis reshaped the treatment paradigm in transthyretin amyloid cardiomyopathy (ATTR-CM) based on a phase-3 randomized controlled trial, but real-world data on its use remain limited. This study aimed to assess in a large, contemporary, real-world cohort of patients with wild-type ATTR-CM (ATTRwt-CM) (i) the clinical phenotype of patients receiving tafamidis, and (ii) the association of tafamidis with survival using propensity-matched observational data.

METHODS AND

RESULTS

Data of patients diagnosed with ATTRwt-CM (January 2017 to June 2023) from 19 Italian centres were analysed. A propensity score (PS) reflecting the likelihood of being treated with tafamidis for each patient was determined using four variables that were significantly different among the two groups: age, New York Heart Association (NYHA) class, National Amyloidosis Centre (NAC) stage and mineralocorticoid receptor antagonists (MRAs). The primary outcome was all-cause mortality. The study comprised 1556 ATTRwt-CM patients: 965 (62%) patients initiated on tafamidis by June 2023 and 591 (38%) patients never treated with disease-modifying therapy. Tafamidis-treated patients were older, exhibited a lower NYHA class and NAC stage, and were more often treated with MRAs compared to untreated patients. The PS-matched cohort comprised 426 patients treated with tafamidis and 426 PS-matched untreated patients (mean age 78.9 ± 5.0 years, 88.3% men, 12.9% in NYHA class III). Adequacy of matching was verified (standardized differences: <0.20 between groups). Over 25 months (interquartile range: 15-40), treatment with tafamidis was associated with lower rates of all-cause mortality (hazard ratio 0.55, 95% confidence interval 0.39-0.77, p = 0.001) across the spectrum of NAC disease stages (p-interaction = 0.94).

CONCLUSIONS

In this large, contemporary, real-world cohort of patients with ATTRwt-CM, predominantly in NYHA class I or II, treatment with tafamidis was consistently associated with a significantly lower risk of all-cause mortality.

Для цитирования: Porcari Aldostefano, Milani Paolo, Longhi Simone, Cappelli Francesco, Vagnarelli Fabio, Aimo Alberto, Cipriani Alberto, Gardini Elisa, Marazia Stefania, Monda Emanuele, Tini Giacomo, Musumeci Beatrice, Serenelli Matteo, Cantone Anna, Lofiego Carla, Marini Marco, Vergaro Giuseppe, Foti Grazia, Musca Francesco, Tomasoni Daniela, Bonacchi Giacomo, Colio Federica, Sinigiani Giulio, De Michieli Laura, Sturdà Francesca, Pozzan Marco, Gentile Piero, Carigi Samuela, Bartolotti Michela, Sena Giuseppe, Ruotolo Irene, Sanna Giuseppe Damiano, Zanoletti Margherita, Canepa Marco, Di Marco Massimo, D'Elia Emilia, Di Bella Gianluca, Driussi Mauro, Imazio Massimo, Perfetto Federico, Biagini Elena, Limongelli Giuseppe, Metra Marco, Emdin Michele, Merlini Giampaolo, Perlini Stefano, Merlo Marco, Palladini Giovanni, Sinagra Gianfranco. Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis.. European journal of heart failure. 2025. DOI: 10.1002/ejhf.70071.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.